{"id":"campath-purged-non-myeloablative-asct","safety":{"commonSideEffects":[{"rate":"null","effect":"Infusion reactions"},{"rate":"null","effect":"Infections"},{"rate":"null","effect":"Thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL450072","moleculeType":"Small molecule","molecularWeight":"140.23"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Alemtuzumab binds to CD52, leading to the depletion of mature lymphocytes, which can help reduce the immune system's attack on the body. This mechanism is often used in the treatment of autoimmune diseases and certain types of cancer.","oneSentence":"Campath (Alemtuzumab) is a monoclonal antibody that targets CD52, a protein found on the surface of mature lymphocytes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:48:04.789Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia (CLL)"}]},"trialDetails":[{"nctId":"NCT00578942","phase":"PHASE2","title":"Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath","status":"COMPLETED","sponsor":"David Rizzieri, MD","startDate":"2005-05","conditions":"Lymphoma, Myeloma, Leukemia","enrollment":48},{"nctId":"NCT00580034","phase":"PHASE2","title":"Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath","status":"COMPLETED","sponsor":"David Rizzieri, MD","startDate":"2003-02","conditions":"Lymphoma, Myeloma, Leukemia","enrollment":176}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Allogeneic Stem Cell Transplant (ASCT)"],"phase":"phase_2","status":"active","brandName":"Campath Purged Non-myeloablative ASCT","genericName":"Campath Purged Non-myeloablative ASCT","companyName":"David Rizzieri, MD","companyId":"david-rizzieri-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Campath (Alemtuzumab) is a monoclonal antibody that targets CD52, a protein found on the surface of mature lymphocytes. Used for Chronic lymphocytic leukemia (CLL).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}